LAB Stock Overview
Labiana Health, S.A. develops, manufactures, sells, and markets animal and human health medicine products in Spain, rest of European Union, and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 5/6 |
| Past Performance | 0/6 |
| Financial Health | 1/6 |
| Dividends | 0/6 |
Labiana Health, S.A. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €1.65 |
| 52 Week High | €3.04 |
| 52 Week Low | €1.05 |
| Beta | 0 |
| 1 Month Change | -2.94% |
| 3 Month Change | 16.20% |
| 1 Year Change | -47.45% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -64.13% |
Recent News & Updates
Recent updates
Shareholder Returns
| LAB | ES Pharmaceuticals | ES Market | |
|---|---|---|---|
| 7D | 6.5% | 0.9% | -1.7% |
| 1Y | -47.5% | 38.9% | 11.3% |
Return vs Industry: LAB underperformed the Spanish Pharmaceuticals industry which returned 39.6% over the past year.
Return vs Market: LAB underperformed the Spanish Market which returned 11.4% over the past year.
Price Volatility
| LAB volatility | |
|---|---|
| LAB Average Weekly Movement | 7.7% |
| Pharmaceuticals Industry Average Movement | 3.6% |
| Market Average Movement | 3.3% |
| 10% most volatile stocks in ES Market | 6.6% |
| 10% least volatile stocks in ES Market | 0.9% |
Stable Share Price: LAB's share price has been volatile over the past 3 months.
Volatility Over Time: LAB's weekly volatility (8%) has been stable over the past year, but is still higher than 75% of Spanish stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1958 | 439 | Manuel Ortega | www.labiana.com |
Labiana Health, S.A. develops, manufactures, sells, and markets animal and human health medicine products in Spain, rest of European Union, and internationally. The company offers anesthetics-sedative, anti-infective, anti-inflammatory, antiparasitic, hormonal, and nutritional products; metabolism regulators; and vitamin products. It also provides sterile, lyophilized, and biological formats; and Fosfomycin trometamol under the Fosfomicina Labiana brand name.
Labiana Health, S.A. Fundamentals Summary
| LAB fundamental statistics | |
|---|---|
| Market cap | €11.75m |
| Earnings (TTM) | -€9.57m |
| Revenue (TTM) | €60.05m |
0.2x
P/S Ratio-1.2x
P/E RatioIs LAB overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| LAB income statement (TTM) | |
|---|---|
| Revenue | €60.05m |
| Cost of Revenue | €30.34m |
| Gross Profit | €29.72m |
| Other Expenses | €39.28m |
| Earnings | -€9.57m |
Last Reported Earnings
Jun 30, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.34 |
| Gross Margin | 49.49% |
| Net Profit Margin | -15.93% |
| Debt/Equity Ratio | 777.8% |
How did LAB perform over the long term?
See historical performance and comparison